BioSpace News Archive

BioMidwest

Skyline Medical Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Listing Requirements

The Company regained compliance with the stockholders’ equity requirement as a result of the completion of two successful financings.

January 12, 2018
·
4 min read
FDA

Myriad Wins FDA OK for BRACAnalysis CDx as Companion Diagnostic for Lynparza (olaparib) in Patients With Metastatic Breast Cancer

BRACAnalysis CDx is the first and only FDA-approved test for use in this indication.

January 12, 2018
·
9 min read
FDA

FDA Green Lights AstraZeneca, Merck’s Lynparza for Metastatic Breast Cancer

Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer.

January 12, 2018
·
19 min read
Business

GENFIT: Half-Year Report of Liquidity Contract With Cic

Under the liquidity contract granted to CIC by GENFIT, the following resources were in the liquidity account as at Decembrer 31, 2017:

January 12, 2018
·
3 min read
Business

Zynex Appoints Two New Independent Board of Directors

Zynex today announced the appointment of Michael Cress, and Barry Michaels to its Board of Directors and Audit Committee.

January 12, 2018
·
3 min read
BioMidwest

Venodol Roll-on, Spotlight Innovation’s New Analgesic Product, Now Available at Amazon.com

Spotlight Innovation today announced that Company subsidiary Caretta Therapeutics’ new over-the-counter chronic pain relief product, Venodol Roll-on, is now available for purchase at Amazon.com.

January 12, 2018
·
3 min read
Business

Primetime Announces a CRADA With NIST to Characterize a Potentially New Class of Antimicrobials

Under this agreement, Primetime will collaborate with Dr. Prasad Reddy who is a recognized expert in chorismate mutase enzymology.

January 12, 2018
·
1 min read
Business

Ambry Taps Former Medtronic Exec as New COO

Mr. Le spent the last 14 years overseeing financial operations at Medtronic’s Diabetes Intensive Insulin Business Unit.

January 12, 2018
·
3 min read
MiMedx to Host Shareholder Call on January 18, 2018 to Update Progress on Multiple Clinical Studies and Status of Patent Portfolio

The Company expects the formal presentation to last approximately 45 minutes, after which the call will be open for questions and answers.

January 12, 2018
·
2 min read
Policy

CanniMed Therapeutics Inc. Launches $725 Million Lawsuit Alleging Multiple Claims of Wrongdoing Related to Aurora Hostile Bid

January 12, 2018
·
6 min read